Clinical Trial Update: A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials [Phase 2]

View source ↗

Summary

Phase 2 open-label extension study to evaluate long-term safety and clinical activity of briquilimab in participants from Jasper Therapeutics' chronic urticaria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urticaria

Drugs mentioned

• Briquilimab

Snippet

Sponsor: Jasper Therapeutics, Inc. | Conditions: Urticaria Chronic | Phase 2 | Status: ACTIVE_NOT_RECRUITING